SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Cronyxin Injection 50 mg/ml Solution for Injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substance:

Flunixin (as Flunixin meglumine) 50 mg

Excipients:

Qualitative composition of excipients and other constituents	**Quantitative composition if that information is essential for proper administration of the veterinary medicinal product**
Phenol (as preservative)	5.0 mg/ml
Sodium Formaldehyde Sulfoxylate (as antioxidant)	2.2 mg/ml
Disodium Edetate Dihydrate	
Propylene Glycol	
Sodium Hydroxide (for pH adjustment)	
Hydrochloric acid (for pH adjustment)	
Water for injections	

Clear, colourless to light yellow solution, free of foreign matter.

3. CLINICAL INFORMATION

3.1 Target species

Cattle and horses.

3.2 Indications for use for each target species

Cattle:
For the control of acute inflammation associated with respiratory disease. It has also been shown to have some benefit in the treatment of experimental acute bovine pulmonary emphysema (Fog fever).

The veterinary medicinal product may be used as adjunctive therapy in the treatment of acute mastitis.

Horses:
For the alleviation of inflammation and pain associated with musculoskeletal disorders.
It is also indicated for the alleviation of visceral pain associated with colic.

3.3 Contraindications

Do not exceed the stated dose or duration of treatment.

Do not use in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastro-intestinal ulceration or bleeding, where this is evidence of blood dyscrasia or hypersensitivity to the veterinary medicinal product.

Do not administer other NSAIDs concurrently or within 24 hours of each other.

Avoid intra-arterial injection.

Avoid use in dehydrated, hypovolaemic or hypotensive animals, as there is a potential risk of increased renal toxicity.

3.4 Special warnings

NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infections, appropriate concurrent antimicrobial therapy should be instigated.

3.5 Special precautions for use

Special precautions for safe use in the target species:
Administer by slow intravenous injection.

Do not mix the veterinary medicinal product with other medicaments prior to administration.

Do not administer to racehorses within 8 days of racing.

Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs to produce an increase in non-bound pharmacologically active concentrations, which can lead to toxic effects.

Use in any animal less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided animals may require a reduced dosage and careful clinical management.

It is preferable that flunixin is not administered to animals undergoing general anaesthesia until fully recovered.

Concurrent administration of potentially nephrotoxic drugs should be avoided.

Special precautions to be taken by the person administering the veterinary medicinal product to animals
Avoid eye contact and direct contact with skin.
To avoid possible sensitisation reactions, avoid contact with skin. Personal protective equipment consisting of gloves should be worn when handling the veterinary medicinal product.
Wash hands after use.
In the case of accidental contact with eyes, rinse immediately with plenty of water and seek medical advice.
The veterinary medicinal product may cause reactions in sensitive individuals. People with known hypersensitivity to non-steroidal anti-inflammatory products should avoid contact with the veterinary medicinal product.
Reactions may be serious. In case of hypersensitivity reactions seek medical advice and show the package leaflet or the label to the physician.
Take care to avoid accidental self-injection.

Special precautions for the protection of the environment:
Not applicable.

3.6 Adverse events

Horses and Cattle:

Undetermined frequency (Cannot be estimated from the available data):	Gastrointestinal irritation[1] Gastrointestinal ulceration[2]

[1]Prolonged use of NSAIDs, including flunixin.
[2]Prolonged use of NSAIDs, including flunixin, in severe cases.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy:
Do not administer to pregnant mares. Studies to demonstrate safety in pregnant mares have not been conducted.

3.8 Interaction with other medicinal products and other forms of interaction

Monitor drug compatibility closely where adjunctive therapy is required. The veterinary medicinal product may potentiate the effects of warfarin and other drugs.

Due to their common mode of action, flunixin may potentiate and be potentiated by other NSAIDs, which act by interfering with prostaglandin synthesis.

3.9 Administration routes and dosage

Intravenous use.

Cattle:
The recommended dose is 2 ml of the veterinary medicinal product per 45 kg bodyweight (equivalent to 2.2 mg flunixin per kg) injected intravenously and repeated as necessary at 24 hour intervals for up to 5 consecutive days. The cause of acute inflammatory conditions should be determined and treated with concomitant therapy.

Horses:
For use in equine musculoskeletal disorders, the recommended dose is 1 ml of the veterinary medicinal product per 45 kg bodyweight (equivalent to 1.1 mg flunixin per kg) injected intravenously and repeated as necessary at 24 hour intervals for up to 5 consecutive days according to clinical response.
For use in equine colic, the recommended dose is 1 ml of the veterinary medicinal product per 45 kg bodyweight (equivalent to 1.1 mg flunixin per kg) injected intravenously and repeated once or twice if signs of colic recur. The cause of colic should be determined and treated with concomitant therapy.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Do not exceed the recommended dose or treat animals for more than 5 consecutive days. Tolerance trials in cattle and horses confirmed excellent tolerance to the veterinary medicinal product at twice the recommended dose.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Cattle:
Meat and offal: 8 days.
Milk: 12 hours.

Horses:
Not authorised for use in horses intended for human consumption.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code:

QM01AG90

4.2 Pharmacodynamics

The veterinary medicinal product is a multidose parenteral product containing flunixin (as flunixin meglumine) 50 mg per ml.
Flunixin Meglumine is a non-steroidal, non-narcotic analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic properties.
It acts by interfering with the arachidonic acid pathway of prostaglandin synthesis.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

None known.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.
Shelf life after first opening the immediate packaging: 28 days.

5.3 Special precautions for storage

Do not store above 25 °C.
Following withdrawal of the first dose, use the product within 28 days.

5.4 Nature and composition of immediate packaging

50 ml & 100 ml clear glass Type I Vial with rubber bromobutyl bung with aluminium overseal.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Bimeda Animal Health Limited

7. MARKETING AUTHORISATION NUMBER

Vm 50146/4011

8. DATE OF FIRST AUTHORISATION

14 March 1996

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

May 2026

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT

Veterinary medicinal product subject to prescription.

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

Gavin Hall
Approved: 19 May 2026